December 8, 2025Blood
TCF3::hlf-positive b-ALL: Largest cohort study to date reveals unique molecular landscape and treatment challenges
Authors
Discussion
Loading...
Member takes
Implication
Largest cohort study reveals treatment challenges and unique molecular features in TCF3::HLF-positive B-ALL, highlighting potential targeted therapies.
Key Points
- To investigate the clinical and molecular characteristics of TCF3::HLF-positive B-ALL, focusing on treatment outcomes.
- Analyzed 34 TCF3::HLF-positive B-ALL patients from 2012 to 2024.
- Conducted multi-dimensional profiling including immunophenotyping, karyotyping, and gene mutation screening.
- Compared findings with other TCF3 fusion subtypes (TCF3::PBX1 and TCF3::ZNF384).
- TCF3::HLF accounted for 1.6% of B-ALL cases, predominantly in pediatric patients.
- High frequency of RAS pathway mutations (86%) identified, with significant immune dysregulation.
- CAR-T therapy led to MRD-negative remission in 13 patients, highlighting its potential in treatment bridge.
Cite This Study
Wang et al. (2025) studied this question.